CLS Health and Houston Food Bank Unite to Fight Hunger in Houston
HOUSTON, TEXAS / ACCESS Newswire / May 19, 2025 / CLS Health, the Houston area's leading physician-owned healthcare group, proudly partnered with the Houston Food Bank for a meaningful day of service on Saturday, April 26. More than 50 employee volunteers and their families gathered for the inaugural CLS CARES event - a company-wide initiative designed to strengthen community ties and give back beyond the clinic.
In just three hours, CLS Health volunteers packed 12 pallets of food, totaling 540 boxes and providing 13,950 meals to seniors experiencing food insecurity across the Greater Houston area.
"We were honored to be a small part of the extraordinary work the Houston Food Bank does every day," said Dr. Mohammed J. Baba, president of CLS Health. ""Healthcare is about compassion and connection and our day of service at the Houston Food Bank is a meaningful opportunity for us to give back to a community we care deeply about.
The event comes at a time when food insecurity remains a pressing issue in Texas. A 2024 poll by No Kid Hungry Texas found that 44% of Texans reported at least one sign of food insecurity in the past year. This included not having enough to eat, eating poor-quality meals, or cutting back due to rising costs.
"Being part of CLS CARES reminds me why I became a physician in the first place - to care deeply, both in and out of the clinic," said Dr. Naureen Alim, CLS Health physician and event participant.
Volunteers spent the afternoon sorting, packing, and preparing food for distribution to seniors throughout the region-a hands-on way to make an immediate and lasting impact.
CLS CARES is a new community engagement initiative that reflects the organization's broader mission: to serve with compassion, build lasting relationships, and improve lives both inside and outside healthcare settings.
"This is just the beginning," added Dr. Baba. "Stay tuned for more community moments from CLS CARES as we continue to invest in the well-being of the neighborhoods we serve."
The event was held at the Houston Food Bank's headquarters, located at 535 Portwall Street.
To learn more about CLS Health's physicians and services, visit cls.health.
About CLS HealthCLS Health is a physician-owned healthcare group with a pioneering approach to comprehensive care. With over 40 locations and more than 200 providers across the Greater Houston area, CLS Health emphasizes the satisfaction and empowerment of its physicians as a key element in delivering exceptional patient care. Learn more at cls.health.
About Houston Food BankServing Houston and southeast Texas since 1982, Houston Food Bank's mission is to provide food for better lives. We provide access to 140 million nutritious meals in 18 counties through our 1,600 community partners of food pantries, soup kitchens, social service providers and schools. Filling gaps on plates, we have a strong focus on healthy foods and fresh produce. In collaboration with our community, we advocate for policy change and racial equity, and promote dialogue on ways to increase access to food and to improve the lives of those in our communities, including services and connections to programs that address the root causes of hunger and are aimed at helping families achieve long-term stability: nutrition education, health management and help with securing state-funded assistance. We are a resource for individuals and families in times of hardship. Houston Food Bank works alongside our partner food banks in Montgomery County, Galveston County and Brazos Valley. Houston Food Bank is a certified member of Feeding America, the nation's food bank network, with a four-star rating from Charity Navigator for the 13th consecutive year.
Website houstonfoodbank.org; Social media: @houstonfoodbank (Instagram and X), @thehoustonfoodbank (Facebook)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80%
NEW YORK CITY, NY / ACCESS Newswire / August 4, 2025 / Traveler Care, a breakthrough medical dispatch platform that brings urgent care directly to travelers in hotels, Airbnbs, and vacation rentals, has officially launched worldwide - offering travel insurance companies a high-impact solution to reduce avoidable emergency room and hospital claims. A Concierge Alternative to the Emergency Room Traveler Care connects travel insurers and their policyholders to a network of licensed, on-call providers who visit travelers in their accommodations - typically within 60-90 minutes. Conditions such as flu, food poisoning, dehydration, allergic reactions, UTIs, sprains, and wound care are treated on-site, eliminating the need for an ER visit. "In most cases, travelers just need a doctor - not a hospital admission," said Eli Ofel, founder of Traveler Care. "We've built a scalable, insurer-ready solution that saves money and delivers a far better traveler experience." Reduce Claims by $10,000+ Per Visit On average, a non-emergency ER visit costs travel insurers $13,000 to $17,000. Traveler Care treats the same conditions in-room for $1,700 to $3,000 - including diagnostics like mobile X-ray, ultrasound, IV therapy, and wound treatment. Pilot results have shown:- 83% reduction in ER claim volume- $10,000+ savings per case avoided- Higher satisfaction scores among travelers Built for Travel Insurance Partners Traveler Care is fully designed for insurance integration - with white-label and API options available for TPAs, underwriters, and global assistance networks. Platform features:- Nationwide U.S. coverage (with international expansion underway)- A robust dispatch network, for example companies like Leaa Health, Sickday, Heal, DocGo and more, any location that the travel insurance is experiencing high volume travel care will create a solution for that particular location within 60 days.- HIPAA-compliant documentation + one-click claims integration- Supports care delivery to hotels, Airbnbs, resorts, and serviced apartments Now Onboarding Insurance Companies Worldwide "We believe travel insurance companies shouldn't just pay for care - they should deliver it smarter," said Ofel. "With Traveler Care, you lower claims without compromising care." Insurance providers, TPAs, and global assistance companies are invited to partner and deploy in-room urgent care as part of their medical benefit stack. Contact To schedule a private demo or receive our ROI case study:Visit partners@ +1 (347) 733-0563 About Eli Ofel Eli Ofel is a serial entrepreneur and visionary behind multiple AI- and tech-powered platforms in healthcare, finance, and transportation. He is the founder and CEO of Traveler Care, Leaa Health, and With over 20 years of experience in healthcare operations, insurance workflows, and mobile logistics, Ofel brings a proven ability to bridge patient needs with scalable platform solutions - saving time, money, and lives. SOURCE: Traveler care press release
The Hill
3 days ago
- The Hill
Number of Texans receiving out-of-state abortions quadrupled between 2021 and 2023
AUSTIN (KXAN) — Texans who sought an abortion out of state more than quadrupled between 2021 and 2023 after a state law went into effect that bans the procedure in almost all cases. Data from the Texas Health and Human Services Commission (HHSC) shows at least 7,844 Texas residents received an abortion in a different state in 2023, up from 4,718 in 2022 and 1,712 in 2021. Still the total number of abortions for Texas residents dropped by 85 percent compared to 2021. In 2023, just 62 abortions were reported in Texas, all due to medical emergency and/or to preserve the health of the mother. In 2024, 76 abortions were performed in the state, according to the HHSC data. Texas receives reports from other states through the State and Territorial Exchange of Vital Events, a public health reporting system maintained by the National Association for Public Health Statistics and Information Systems. Reporting abortion data to the system is voluntary, and not all states participate, according to a HHSC spokesperson. That means the total number may be higher than the 7,844 reported in 2023. In fact, the Guttmacher Institute, a non-profit that tracks access to abortion, estimates the number to be closer to 35,000. The organization estimates 14,230 Texas women traveled to New Mexico for an abortion in 2023, while 6,620 went to Kansas, 4,440 went to Colorado and 3,310 went to California. An estimated 6,300 Texas women went to other states. In 2022, almost 3,000 Texans received an abortion in Kansas, according to official data from the Kansas Department of Health and Environment. That constituted a 1,178 percent increase from 2021, when just 233 abortions were performed on Texas residents. Kansas has yet to report data for 2023. HHSC does not maintain data on people who travel internationally to receive an abortion. The Supreme Court struck down Roe v. Wade in a 6-3 decision on June 24, 2022, eliminating the nearly 50-year-old constitutional right to abortion. The ruling gave states the authority to limit or ban the procedure. A trigger law in Texas went into effect in August 2022, banning most abortions in the state. Abortion is also banned in neighboring Arkansas, Louisiana and Oklahoma, meaning Texas women who want the procedure must travel to states like Kansas, Colorado and New Mexico.
Indianapolis Star
7 days ago
- Indianapolis Star
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals ( Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC ®) in Toronto. This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20). The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease. No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC 0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%). Abidin Gülmüş, Chairman of GEN, stated: 'We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease.' Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added: 'With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.' About SUL-238 SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's 'powerhouse.' It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications. About GEN: Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments. About Sulfateq: Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health. Contact Information Bulutay Güneş Sr. Head of Corporate Brand Ali Ketencioğlu Investor Relations Manager Kees van der Graaf Sulfateq CEO View the original press release on ACCESS Newswire The post GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases appeared first on DA80 Hub.
